Joele Frank and Huntsworth's Citigate First Financial represent Jerusalem-based Teva Pharmaceutical Industries' audacious $40B bid to acquire Mylan NV to create the globe's biggest generic drug company.
If completed, the deal would be the largest healthcare deal of 2015.
Currently Mylan is waging a nearly $30B takeover of Ireland's Perrigo Co, an offer that yesterday officially received the cold shoulder.
Teva believes its deal is a better proposal for Myan stockholders compared to the Perrigo transaction.
The potential acquirer sees Mylan as a "natural fit" and a way to shore up the ability to counter "knock-off" drugs.
Mylan, on April 17, said it saw little benefit in a hook-up with Teva.
To counter media speculation about a Teva deal, Robert Coury, Mylan executive chairman, then said, "It is clear that such a combination is without sound industrial logic or cultural fit."
He said Mylan is committed to a stand-alone strategy and wrapping up the Perrigo transaction.
Joele Frank PR shop reps Teva in the US, while Citigate handles media in Holland, where Mylan recently re-incorporated in a shift from Pennsylvania.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Intelligent Group Ltd, a Hong Kong-based financial PR firm, has priced its initial public offering of 1.9M shares at $4, which is the low end of the $4 to $5 range.
Kekst CNC represents Grant Thornton as it sells a majority stake in its US arm to New Mountain Capital, which relies on Goldin Solutions, in what is billed as the largest PE investment in the accounting and advisory sector.
Have a comment? Send it to 
No comments have been submitted for this story yet.